Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Metagenomi Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was $61.13 Mil. Metagenomi Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $173.70 Mil.
Therefore, Metagenomi Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.35.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Metagenomi Therapeutics Liabilities-to-Assets Related Terms
Metagenomi Therapeutics Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Metagenomi Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGX vs TVGN, VERU, GRCE: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Metagenomi Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Metagenomi Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a Liabilities-to-Assets of 0.35 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Liabilities-to-Assets too high?
Metagenomi Therapeutics' current Liabilities-to-Assets is 0.35. Overall, Metagenomi Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Liabilities-to-Assets compare to TVGN and VERU?
Metagenomi Therapeutics' Liabilities-to-Assets of 0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Liabilities-to-Assets is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $1.12 — trading 49.3% above its estimated fair value. The current Liabilities-to-Assets is 0.35. Metagenomi Therapeutics' overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Liabilities-to-Assets is 0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metagenomi Therapeutics (MGX) Overvalued in 2026?
Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued.
The current stock price of $1.12 is trading 49.3% above its estimated GF Value™ of $0.75.
GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.
Key valuation signals for MGX:
Liabilities-to-Assets: 0.35
GF Value™: $0.75 vs. price of $1.12 (49.3% above fair value)
No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
8GF Score
Get the complete analysis for MGX
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
